{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:26:43Z","timestamp":1776400003429,"version":"3.51.2"},"reference-count":81,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IPO Porto","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}]},{"name":"IPO Porto","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}]},{"name":"IPO Porto","award":["UIDB\/00776\/2020-3"],"award-info":[{"award-number":["UIDB\/00776\/2020-3"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","award":["UIDB\/00776\/2020-3"],"award-info":[{"award-number":["UIDB\/00776\/2020-3"]}]},{"name":"FCT\/MCTES","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}]},{"name":"FCT\/MCTES","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}]},{"name":"FCT\/MCTES","award":["UIDB\/00776\/2020-3"],"award-info":[{"award-number":["UIDB\/00776\/2020-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Ovarian cancer (OC) is a leading cause of death among gynaecological malignancies. The haemostatic system, which controls blood flow and prevents clotting disorders, paradoxically drives OC progression while increasing the risk of venous thromboembolism (VTE). MicroRNAs (miRNAs) have emerged as crucial in understanding VTE pathogenesis. Exploring the connection between cancer and thrombosis through these RNAs could lead to novel biomarkers of cancer-associated thrombosis (CAT) and OC, as well as potential therapeutic targets for tumour management. Thus, this study examined the impact of eight plasma miRNAs targeting the tissue factor (TF) coagulation pathway\u2014miR-18a-5p, -19a-3p, -20a-5p, -23a-3p, -27a-3p, -103a-3p, -126-5p and -616-3p\u2014in 55 OC patients. Briefly, VTE occurrence post-OC diagnosis was linked to shorter disease progression time (log-rank test, p = 0.024) and poorer overall survival (OS) (log-rank test, p &lt; 0.001). High pre-chemotherapy levels of miR-20a-5p (targeting coagulation factor 3 (F3) and tissue factor pathway inhibitor 2 (TFPI2)) and miR-616-3p (targeting TFPI2) predicted VTE after OC diagnosis (\u03c72, p &lt; 0.05). Regarding patients\u2019 prognosis regardless of VTE, miR-20a-5p independently predicted OC progression (adjusted hazard ratio (aHR) = 6.13, p = 0.005), while miR-616-3p significantly impacted patients\u2019 survival (aHR = 3.72, p = 0.020). Further investigation is warranted for their translation into clinical practice.<\/jats:p>","DOI":"10.3390\/biom14080928","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T12:38:20Z","timestamp":1722515900000},"page":"928","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Plasma microRNA Environment Linked to Tissue Factor Pathway and Cancer-Associated Thrombosis: Prognostic Significance in Ovarian Cancer"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-7757","authenticated-orcid":false,"given":"Val\u00e9ria","family":"Tavares","sequence":"first","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Dep., Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Centre (Porto. CCC), 4200-072 Porto, Portugal"},{"name":"ICBAS\u2014Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto (FMUP), 4200-072 Porto, Portugal"}]},{"given":"Joana","family":"Savva-Bordalo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"given":"Mariana","family":"Rei","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9150-4180","authenticated-orcid":false,"given":"Joana","family":"Liz-Pimenta","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Porto (FMUP), 4200-072 Porto, Portugal"},{"name":"Department of Medical Oncology, Centro Hospitalar de Tr\u00e1s-os-Montes e Alto Douro (CHTMAD), 5000-508 Vila Real, Portugal"}]},{"given":"Joana","family":"Assis","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto. CCC), 4200-072 Porto, Portugal"}]},{"given":"Deolinda","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-8373","authenticated-orcid":false,"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Dep., Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Centre (Porto. CCC), 4200-072 Porto, Portugal"},{"name":"ICBAS\u2014Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto (FMUP), 4200-072 Porto, Portugal"},{"name":"Faculty of Health Sciences, Fernando Pessoa University, 4200-150 Porto, Portugal"},{"name":"Research Department, Portuguese League Against Cancer (NRNorte), 4200-172 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J.E.M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.fr\/today."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13048-022-01020-1","article-title":"Maintenance therapy for newly diagnosed epithelial ovarian cancer\u2014A review","volume":"15","author":"Nag","year":"2022","journal-title":"J. Ovarian Res."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tavares, V., Marques, I.S., Melo, I.G.d., Assis, J., Pereira, D., and Medeiros, R. (2024). Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031845"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103989","DOI":"10.1016\/j.critrevonc.2023.103989","article-title":"Thrombosis and cachexia in cancer: Two partners in crime?","volume":"186","author":"Tavares","year":"2023","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tavares, V., Neto, B.V., Marques, I.S., Assis, J., Pereira, D., and Medeiros, R. (2023). Cancer-associated thrombosis: What about microRNAs targeting the tissue factor coagulation pathway?. Biochim. Biophys. Acta (BBA) Rev. Cancer, 1879.","DOI":"10.1016\/j.bbcan.2023.189053"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Oncul, S., and Cho, M.S. (2023). Interactions between platelets and tumor microenvironment components in ovarian cancer and their implications for treatment and clinical outcomes. Cancers, 15.","DOI":"10.3390\/cancers15041282"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Toden, S., Zumwalt, T.J., and Goel, A. (2021). Non-coding RNAs and potential therapeutic targeting in cancer. Biochim. Biophys. Acta (BBA) Rev. Cancer, 1875.","DOI":"10.1016\/j.bbcan.2020.188491"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Correia de Sousa, M., Gjorgjieva, M., Dolicka, D., Sobolewski, C., and Foti, M. (2019). Deciphering miRNAs\u2019 action through miRNA editing. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246249"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1699","DOI":"10.1002\/cnr2.1699","article-title":"Systematic study of tissue factor expression in solid tumors","volume":"6","author":"Harris","year":"2023","journal-title":"Cancer Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.thromres.2013.09.016","article-title":"Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer-relationship with venous thrombosis risk","volume":"132","author":"Saadeh","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.bjc.6603552","article-title":"Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer","volume":"96","author":"Uno","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/IGC.0000000000000848","article-title":"Expression of tissue factor in epithelial ovarian carcinoma is involved in the development of venous thromboembolism","volume":"27","author":"Sakurai","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/IGC.0b013e3182150e98","article-title":"Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism","volume":"21","author":"Ma","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Steidel, C., Ender, F., Rody, A., von Bubnoff, N., and Gieseler, F. (2021). Biologically active tissue factor-bearing larger Ectosome-like extracellular vesicles in malignant effusions from ovarian cancer patients: Correlation with incidence of thrombosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020790"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/jog.15770","article-title":"Tissue factor pathway inhibitor 2: Current understanding, challenges, and future perspectives","volume":"49","author":"Kobayashi","year":"2023","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_16","first-page":"2997","article-title":"Tissue factor\/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism","volume":"63","author":"Hembrough","year":"2003","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Marques, I.S., Tavares, V., Savva-Bordalo, J., Rei, M., Liz-Pimenta, J., de Melo, I.G., Assis, J., Pereira, D., and Medeiros, R. (2023). Long Non-Coding RNAs: Bridging Cancer-Associated Thrombosis and Clinical Outcome of Ovarian Cancer Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010140"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tavares, V., Savva-Bordalo, J., Rei, M., Liz-Pimenta, J., Assis, J., Pereira, D., and Medeiros, R. (2024). Haemostatic Gene Expression in Cancer-Related Immunothrombosis: Contribution for Venous Thromboembolism and Ovarian Tumour Behaviour. Cancers, 16.","DOI":"10.3390\/cancers16132356"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_20","first-page":"4902","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1074\/jbc.M110.146530","article-title":"MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells","volume":"286","author":"Zhang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_22","unstructured":"Eisenreich, A., and Rauch, U. (2013). Regulation of the tissue factor isoform expression and thrombogenicity of HMEC-1 by miR-126 and miR-19a. Cell Biol. Res. Ther., 2."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11010-013-1679-6","article-title":"MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion","volume":"380","author":"Yu","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1076397","DOI":"10.1155\/2017\/1076397","article-title":"miR-19a and miR-20a and tissue factor expression in activated human peripheral blood mononuclear cells","volume":"2017","author":"Balia","year":"2017","journal-title":"Thrombosis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-018-0678-z","article-title":"MicroRNA-19a contributes to the epigenetic regulation of tissue factor in diabetes","volume":"17","author":"Witkowski","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.2147\/CMAR.S207677","article-title":"Berberine induces apoptosis in non-small-cell lung cancer cells by upregulating miR-19a targeting tissue factor","volume":"11","author":"Chen","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhang, R., Lu, S., Yang, X., Li, M., Jia, H., Liao, J., Jing, Q., Wu, Y., Wang, H., and Xiao, F. (2021). miR-19a-3p downregulates tissue factor and functions as a potential therapeutic target for sepsis-induced disseminated intravascular coagulation. Biochem. Pharmacol., 192.","DOI":"10.1016\/j.bcp.2021.114671"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Oto, J., Navarro, S., Larsen, A.C., Solmoirago, M.J., Plana, E., Herv\u00e1s, D., Fern\u00e1ndez-Pardo, \u00c1., Espa\u00f1a, F., Kristensen, S.R., and Thorlacius-Ussing, O. (2020). MicroRNAs and neutrophil activation markers predict venous thrombosis in pancreatic ductal adenocarcinoma and distal extrahepatic cholangiocarcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030840"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2011.04451.x","article-title":"Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome","volume":"9","author":"Teruel","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/scrt332","article-title":"MicroRNA-20b and ERK1\/2 pathway independently regulate the expression of tissue factor in hematopoietic and trophoblastic differentiation of human embryonic stem cells","volume":"4","author":"Yu","year":"2013","journal-title":"Stem Cell Res. Ther."},{"key":"ref_31","first-page":"53","article-title":"MicroRNA-23a acts as an oncogene in pancreatic carcinoma by targeting TFPI-2","volume":"20","author":"Wang","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Oto, J., Plana, E., Solmoirago, M.J., Fern\u00e1ndez-Pardo, \u00c1., Herv\u00e1s, D., Cana, F., Espa\u00f1a, F., Artoni, A., Bucciarelli, P., and Carrabba, G. (2020). microRNAs and markers of neutrophil activation as predictors of early incidental post-surgical pulmonary embolism in patients with intracranial tumors. Cancers, 12.","DOI":"10.3390\/cancers12061536"},{"key":"ref_33","first-page":"19","article-title":"Diagnostic value of circulating microRNA-27a\/b in patients with acute pulmonary embolism","volume":"37","author":"Wang","year":"2017","journal-title":"Int. Angiol. J. Int. Union Angiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jth.13321","article-title":"The role of micro RNA-27a\/b and micro RNA-494 in estrogen-mediated downregulation of tissue factor pathway inhibitor \u03b1","volume":"14","author":"Ali","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e3166","DOI":"10.1002\/jgm.3166","article-title":"Low abundance of TFPI-2 by both promoter methylation and miR-27a-3p regulation is linked with poor clinical outcome in gastric cancer","volume":"22","author":"Geng","year":"2020","journal-title":"J. Gene Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/iub.2168","article-title":"Overexpressed microRNA-103a-3p inhibits acute lower-extremity deep venous thrombosis via inhibition of CXCL12","volume":"72","author":"Sun","year":"2020","journal-title":"IUBMB Life"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13148-019-0627-z","article-title":"Association of recurrent venous thromboembolism and circulating microRNAs","volume":"11","author":"Wang","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/ATVBAHA.120.314092","article-title":"Identification of a plasma MicroRNA profile associated with venous thrombosis","volume":"40","author":"Lopez","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1055\/s-0041-1726341","article-title":"MiRNA 126 as a new predictor biomarker in venous thromboembolism of persistent residual vein obstruction: A review of the literature plus a pilot study","volume":"47","author":"Rossetti","year":"2021","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_40","first-page":"583","article-title":"MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2","volume":"71","author":"Ma","year":"2011","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e12490","DOI":"10.1111\/cpr.12490","article-title":"MiR-616-3p modulates cell proliferation and migration through targeting tissue factor pathway inhibitor 2 in preeclampsia","volume":"51","author":"Xu","year":"2018","journal-title":"Cell Prolif."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Silva, J., Tavares, V., Afonso, A., Garcia, J., Cerqueira, F., and Medeiros, R. (2023). Plasmatic MicroRNAs and Treatment Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer: A Hospital-Based Cohort Study and In Silico Analysis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24109101"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ijc.28757","article-title":"Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients","volume":"135","author":"Hu","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ymeth.2012.09.015","article-title":"Assessing sample and miRNA profile quality in serum and plasma or other biofluids","volume":"59","author":"Blondal","year":"2013","journal-title":"Methods"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Shah, J.S., Soon, P.S., and Marsh, D.J. (2016). Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153200"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.gendis.2022.08.011","article-title":"Is there a potential of circulating miRNAs as biomarkers in rheumatic diseases?","volume":"10","year":"2023","journal-title":"Genes Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.trecan.2021.12.008","article-title":"Coagulome and the tumor microenvironment: An actionable interplay","volume":"8","author":"Galmiche","year":"2022","journal-title":"Trends Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100129","DOI":"10.1016\/j.tru.2022.100129","article-title":"Bleeding and venous thromboembolism events in cancer patients taking direct oral anticoagulants vs. low molecular weight heparin","volume":"10","author":"Lattuca","year":"2023","journal-title":"Thromb. Update"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wang, J., Peng, X., Li, R., Liu, K., Zhang, C., Chen, X., Huang, G., Zhao, L., Chen, Z., and Lai, Y. (2021). Evaluation of serum miR-17-92 cluster as noninvasive biomarkers for bladder cancer diagnosis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.795837"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.avsg.2019.10.048","article-title":"Downregulation of miR-103a-3p contributes to endothelial progenitor cell dysfunction in deep vein thrombosis through PTEN targeting","volume":"64","author":"Zhang","year":"2020","journal-title":"Ann. Vasc. Surg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6256384","DOI":"10.1155\/2022\/6256384","article-title":"Knockdown of lncRNA XIST Ameliorates IL-1\u03b2-Induced Apoptosis of HUVECs and Change of Tissue Factor Level via miR-103a-3p\/HMGB1 Axis in Deep Venous Thrombosis by Regulating the ROS\/NF-\u03baB Signaling Pathway","volume":"2022","author":"Cao","year":"2022","journal-title":"Cardiovasc. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/jcp.28958","article-title":"Interactive Functions of microRNAs in the miR-23a-27a-24-2 Cluster and the Potential for Targeted Therapy in Cancer","volume":"235","author":"Cui","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.reprotox.2021.12.011","article-title":"MicroRNA-20a-5p inhibits the autophagy and cisplatin resistance in ovarian cancer via regulating DNMT3B-mediated DNA methylation of RBP1","volume":"109","author":"Li","year":"2022","journal-title":"Reprod. Toxicol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/abbs\/gmq026","article-title":"miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells","volume":"42","author":"Fan","year":"2010","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3892\/ol.2017.6348","article-title":"MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line","volume":"14","author":"Liu","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/cmi.2014.30","article-title":"Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA\/B expression","volume":"11","author":"Xie","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000524804","article-title":"Tissue factor pathway inhibitor 2: A novel biomarker for predicting asymptomatic venous thromboembolism in patients with epithelial ovarian cancer","volume":"87","author":"Yamanaka","year":"2022","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/mco.2021.2479","article-title":"Tissue factor pathway inhibitor 2 as a serum marker for diagnosing asymptomatic venous thromboembolism in patients with epithelial ovarian cancer and positive D-dimer results","volume":"16","author":"Miyake","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3892\/ol.2024.14435","article-title":"Investigating the efficacy of tissue factor pathway inhibitor-2 as a promising prognostic marker for ovarian cancer","volume":"28","author":"Maehana","year":"2024","journal-title":"Oncol. Lett."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Arakawa, N., Kobayashi, H., Yonemoto, N., Masuishi, Y., Ino, Y., Shigetomi, H., Furukawa, N., Ohtake, N., Miyagi, Y., and Hirahara, F. (2016). Clinical significance of tissue factor pathway inhibitor 2, a serum biomarker candidate for ovarian clear cell carcinoma. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165609"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s10147-021-01914-y","article-title":"Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary","volume":"26","author":"Miyagi","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/03007995.2023.2208488","article-title":"Clear cell carcinoma of the ovary and venous thromboembolism: A systematic review and meta-analysis","volume":"39","author":"Didar","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41397-020-00201-9","article-title":"Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients","volume":"21","author":"Tavares","year":"2021","journal-title":"Pharmacogenom. J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.1038\/s41598-023-36161-w","article-title":"Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer","volume":"13","author":"Neto","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3109\/0284186X.2013.705890","article-title":"Early growth response gene-1 and hypoxia-inducible factor-1\u03b1 affect tumor metastasis via regulation of tissue factor","volume":"52","author":"Sun","year":"2013","journal-title":"Acta Oncol."},{"key":"ref_67","first-page":"1355","article-title":"Diverse roles of cell-specific hypoxia-inducible factor 1 in cancer-associated hypercoagulation","volume":"127","author":"Evans","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1049\/syb2.12071","article-title":"Deep sequencing of circulating miRNAs and target mRNAs level in deep venous thrombosis patients","volume":"17","author":"Wang","year":"2023","journal-title":"IET Syst. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1161\/CIRCRESAHA.119.315259","article-title":"Activated endothelial TGF\u03b21 signaling promotes venous thrombus nonresolution in mice via endothelin-1: Potential role for chronic thromboembolic pulmonary hypertension","volume":"126","author":"Bochenek","year":"2020","journal-title":"Circ. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/cpr.12262","article-title":"Cell-free microRNAs in blood and other body fluids, as cancer biomarkers","volume":"49","year":"2016","journal-title":"Cell Prolif."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13048-022-00979-1","article-title":"The molecular mechanism of circRHOBTB3 inhibits the proliferation and invasion of epithelial ovarian cancer by serving as the ceRNA of miR-23a-3p","volume":"15","author":"Fu","year":"2022","journal-title":"J. Ovarian Res."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Zhang, M., Sun, Y., Xu, H., Shi, Y., Shen, R., Teng, F., Xu, J., and Jia, X. (2023). Circular RNA hsa_circ_0007444 inhibits ovarian cancer progression through miR-23a-3p\/DICER1 axis: Hsa_circ_0007444\/miR-23a-3p\/DICER1 in ovarian cancer. Acta Biochim. Biophys. Sin., 55.","DOI":"10.21203\/rs.3.rs-1802884\/v2"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21037\/atm-22-6394","article-title":"lncRNA GAS5 suppression of the malignant phenotype of ovarian cancer via the miR-23a-WT1 axis","volume":"11","author":"Zhou","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Todeschini, P., Salviato, E., Romani, C., Raimondi, V., Ciccarese, F., Ferrari, F., Tognon, G., Marchini, S., D\u2019Incalci, M., and Zanotti, L. (2021). Comprehensive profiling of hypoxia-related miRNAs identifies miR-23a-3p overexpression as a marker of platinum resistance and poor prognosis in high-grade serous ovarian cancer. Cancers, 13.","DOI":"10.3390\/cancers13133358"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Lin, H., Shen, L., Lin, Q., Dong, C., Maswela, B., Illahi, G.S., and Wu, X. (2020). SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a. Biomed. Pharmacother., 123.","DOI":"10.1016\/j.biopha.2019.109711"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/AGG.S86586","article-title":"MicroRNA activity profile in the ovarian cancer cell line OVCAR3 identifies a proapoptotic effect of miR-23a","volume":"2015","author":"Andikyan","year":"2015","journal-title":"Adv. Genom. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.2147\/JIR.S439205","article-title":"Recent Advances on the Molecular Mechanism and Clinical Trials of Venous Thromboembolism","volume":"16","author":"Huang","year":"2023","journal-title":"J. Inflamm. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.bbrc.2018.05.109","article-title":"MiR-616-3p promotes angiogenesis and EMT in gastric cancer via the PTEN\/AKT\/mTOR pathway","volume":"501","author":"Wu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_79","first-page":"2960","article-title":"MicroRNA-616 promotes the progression of ovarian cancer by targeting TIMP2","volume":"39","author":"Chen","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_80","first-page":"2348","article-title":"miR-616 promotes breast cancer migration and invasion by targeting TIMP2 and regulating MMP signaling","volume":"18","author":"Yuan","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Marques, I.S., Tavares, V., Neto, B.V., Mota, I.N.R., Pereira, D., and Medeiros, R. (2023). Long Non-Coding RNAs in Venous Thromboembolism: Where Do We Stand?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512103"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/8\/928\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:27:24Z","timestamp":1760110044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/8\/928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":81,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["biom14080928"],"URL":"https:\/\/doi.org\/10.3390\/biom14080928","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}